Menu Search
Equities

Chengdu Olymvax Biopharmaceuticals Inc

688319:SHH

Chengdu Olymvax Biopharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.38
  • Today's Change-0.03 / -0.36%
  • Shares traded694.32k
  • 1 Year change-52.09%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Chengdu Olymvax Biopharmaceuticals Inc's revenues fell -9.38% from 547.48m to 496.12m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 26.58m to 17.56m, a -33.94% decrease.
Gross margin93.59%
Net profit margin-9.35%
Operating margin-10.41%
Return on assets-2.91%
Return on equity-4.34%
Return on investment-4.18%
More ▼

Cash flow in CNYView more

In 2023, Chengdu Olymvax Biopharmaceuticals Inc increased its cash reserves by 36.16%, or 94.42m. Cash Flow from Financing totalled 129.27m or 26.06% of revenues. In addition the company generated 44.00m in cash from operations while cash used for investing totalled 78.84m.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.17
Tangible book value per share1.54
More ▼

Balance sheet in CNYView more

Chengdu Olymvax Biopharmaceuticals Inc has a Debt to Total Capital ratio of 28.60%, a higher figure than the previous year's 9.46%.
Current ratio1.83
Quick ratio1.65
Total debt/total equity0.4056
Total debt/total capital0.286
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.